ArticleOncogene2013
Context-dependent differences in miR-10b breast oncogenesis can be targeted for the prevention and arrest of lymph node metastasis.
Article in Oncogene, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 90 citations in OpenAlex.
- Targeting miR-10b in Breast Cancer Bone Colonization Model Using Image-Guided Nucleic Acid-Based Therapeutics.Cancers · 2026Article
- Review
- Template-Directed RIG-I Agonist Assembly for Image-guided Targeted Cancer Immunotherapy.Molecular imaging and biology · 2026Article
- Nanotherapy Targeting miR-10b Improves Survival in Orthotopic Glioblastoma Models.Journal of functional biomaterials · 2025Article
- Target-Responsive DNA Hydrogels with Encapsulation and Release Properties Using Programmable CRISPR-Cas12a.ACS chemical biology · 2025Article
- Inhibition of miR-10b treats metastatic breast cancer by targeting stem cell-like properties.Oncotarget · 2024Article
- Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases.Journal of visualized experiments : JoVE · 2024Article
- Imaging of Endometriotic Lesions Using cRGD-MN Probe in a Mouse Model of Endometriosis.Nanomaterials (Basel, Switzerland) · 2024Article
- Omniparticle Contrast Agent for Multimodal Imaging: Synthesis and Characterization in an Animal Model.Molecular imaging and biology · 2023Article
- Co-administration of temozolomide (TMZ) and the experimental therapeutic targeting miR-10b, profoundly affects the tumorigenic phenotype of human glioblastoma cells.Frontiers in molecular biosciences · 2023Article
- miRNA: A Promising Therapeutic Target in Cancer.International journal of molecular sciences · 2022Review
- Significance of metastamiR-10b in breast cancer therapeutics.Journal of the Egyptian National Cancer Institute · 2022Review
- Case report: MicroRNA-10b as a therapeutic target in feline metastatic mammary carcinoma and its implications for human clinical trials.Frontiers in oncology · 2022Article
- microRNA-based diagnostic and therapeutic applications in cancer medicine.Wiley interdisciplinary reviews. RNA · 2021Review
- MiRNA10b-directed nanotherapy effectively targets brain metastases from breast cancer.Scientific reports · 2021Article
- Radiolabeling and PET-MRI microdosing of the experimental cancer therapeutic, MN-anti-miR10b, demonstrates delivery to metastatic lesions in a murine model of metastatic breast cancer.Cancer nanotechnology · 2021Article
- Switchable Fluorescence of Doxorubicin for Label-Free Imaging of Bioorthogonal Drug Release.ChemMedChem · 2020Article
- Improving the therapeutic efficiency of noncoding RNAs in cancers using targeted drug delivery systems.Drug discovery today · 2020Review
- Screening of potential miRNA therapeutics for the prevention of multi-drug resistance in cancer cells.Scientific reports · 2020Article
- MicroRNA replacement therapy in cancer.Journal of cellular physiology · 2019Review
Corrections and comments
- Erratum issued
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
Metastases, and not the primary tumor from which they originate, are the main reason for mortality from carcinoma. Although the molecular mechanisms behind metastasis are poorly understood, it is clear that epigenetic dysregulation at the level of microRNA expression is a key characteristic of the metastatic process that can be exploited for therapy. Here, we describe an miRNA-targeted therapeutic approach for the prevention and arrest of lymph node metastasis. Therapy relies on the inhibition of the pro-metastatic microRNA-10b. It is delivered to primary and lymph node metastatic tumor cells using an imaging-capable nanodrug that is designed to specifically home to these tissues. Treatment of invasive human breast tumor cells (MDA-MB-231) with the nanodrug in vitro downregulates miR-10b and abolishes the invasion and migration of the tumor cells. After intravenous delivery to mice bearing orthotopic MDA-MB-231-luc-D3H2LN tumors, the nanodrug accumulates in the primary tumor and lymph nodes. When treatment is initiated before metastasis to lymph nodes, metastasis is prevented. Treatment after the formation of lymph node metastases arrests the metastatic process without a concomitant effect on primary tumor growth raising the possibility of a context-dependent variation in miR-10b breast oncogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.